Sensei Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNSE research report →
Range $50 – $50
Price Chart
About the company
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform.
- CEO
- Christopher W. Gerry
- IPO
- 2021
- Employees
- 14
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on SNSE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.59M
- P/E
- -0.23
- PEG
- 0.00
- P/S
- -170.58
- P/B
- 1.05
- EV/EBITDA
- -4.10
- Div Yield
- 0.00%
- Gross Margin
- 2740.82%
- Op Margin
- 4098.54%
- Net Margin
- 4030.69%
- ROE
- -192.76%
- ROIC
- -110.26%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-22,288,000
- Net Income
- $-21,085,000+30.1%
- EPS
- $-16.72-1293.3%
- OCF Growth
- +17.1%
- FCF Growth
- +17.5%
- 52W High
- $36.76
- 52W Low
- $6.33
- 50D MA
- $21.49
- 200D MA
- $16.71
- Beta
- -0.23
- RSI (14)
- 69
- Avg Volume
- 52.33K
No earnings-call transcripts are available for SNSE yet.
- Free Float
- 60.5%
- Shares Outstanding
- 1.34M
- Float Shares
- 811.87K
of shares held by institutions
10 13F filers
Buy/sell ratio 0.72. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Raymond James & Associates | 20.00K | ▲ 6.00K |
| Blackrock Inc. | 7.78K | ▼ 25.80K |
Our SNSE coverage
Recent articles, reports, and earnings notes.
No research on SNSE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNSE report →Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
businesswire.com · Jun 15
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
gurufocus.com · Jun 4
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Jun 4
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
gurufocus.com · May 15
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
businesswire.com · May 15
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
businesswire.com · May 5
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
businesswire.com · Apr 9
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
businesswire.com · Mar 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.